InvestorsObserver
×
News Home

Is it Time to Dump ZIOPHARM Oncology Inc. (ZIOP) Stock After it Has Fallen 3.10% in a Week?

Thursday, December 16, 2021 11:22 AM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump ZIOPHARM Oncology Inc. (ZIOP) Stock After it Has Fallen 3.10% in a Week?

ZIOPHARM Oncology Inc. (ZIOP) stock is lower by 3.10% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
ZIOPHARM Oncology Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ZIOP!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ZIOP Stock Today?

ZIOPHARM Oncology Inc. (ZIOP) stock is trading at $1.25 as of 11:21 AM on Thursday, Dec 16, a loss of -$0.01, or -1.19% from the previous closing price of $1.26. The stock has traded between $1.20 and $1.27 so far today. Volume today is less active than usual. So far 300,366 shares have traded compared to average volume of 2,352,790 shares.

More About ZIOPHARM Oncology Inc.

ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad. Click Here to get the full Stock Report for ZIOPHARM Oncology Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App